Navigation Links
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Date:10/27/2009

FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7 million for the third quarter 2008. Basic income per common share for the quarter was $1.38. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $1.70, an increase of 25 percent over the comparable figure of $1.36 for the same period in 2008. Adjusted net income for the third quarter of 2009 was $126.7 million, a 36 percent increase over the comparable $92.9 million for the third quarter of 2008. This exceeded the company's adjusted net income guidance range of $108 to $116 million.

Central nervous system (CNS) franchise net sales were $291.9 million during the quarter, a 7 percent increase compared to the same period last year. Pain franchise reported net sales of $116.3 million, a 1 percent decrease versus third quarter 2008. Oncology franchise net sales were $83.1 million, a 58 percent increase over the same period last year due to strong sales of TREANDA® (bendamustine hydrochloride) of $54.5 million.

During the quarter Cephalon recorded net cash provided by operating activities of $203.6 million bringing the year-to-date cash flow from operations to $517.1 million.

"The exceptional launch of NUVIGIL was the highlight of the quarter," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "In addition, we have assembled the deepest and most diverse pipeline in our history with a variety of small molecules and biologics being studied for pain, oncology, and inflammatory diseases. We look forward to developing this diverse pipeline with the goal of creating important new medicines for patients."

The company is updating its guidance for 2009.
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59%... -- BEIJING, Aug. 16 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets -- LAIYANG, China, Aug. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
Cached Medicine Technology:Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 2Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 3Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 4Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 5Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 6Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 7Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 8Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 9Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 10Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 11Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27 12Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 2Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 3Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 4Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 5Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 6Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets 7
(Date:12/26/2014)... 2014 Cooking and warming equipment ... of 5. This score reflects slightly positive negotiation conditions ... specialization, low switching costs and a low level of ... low availability of substitutes for cooking and warming equipment ... and aluminum, key inputs in the production process of ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... Against the backdrop of last week,s Congressional hearing into ... at Buffalo,s Laboratory for Forensic Odontology Research in the ... on the controversial topic of bitemark analysis. The Congressional ... of Sciences (NAS) report on the scientific basis of ...
... Sept. 16 Managed Health Care Associates, Inc. (MHA), ... the country, today announced the immediate availability of RxPertise ... Regimen Review (MRR) software for consultant pharmacists in the ... efficiently manage the utilization, outcomes, and reporting requirements for ...
... abuse among undergrads, study shows , WEDNESDAY, Sept. 16 ... among university students, but an Internet-based intervention may help ... , Researchers analyzed data from a Web-based alcohol-use screening ... aged 17 to 24, in Australia, and found that ...
... The most important voice is YOURS! ... The Pennsylvania Breast Cancer Coalition (PBCC) Annual Conference will be held on ... 8:30 a.m. to 3:30 p.m. , , ... Pennsylvania Breast Cancer Coalition Annual Conference is the only statewide breast cancer ...
... , , , ... California hospital industry, El Camino Hospital CEO, Ken Graham, will provide insight ... Healthcare CEO Summit on Sept. 17 at 7:15 a.m. at the Rotary ... leadership, Graham has much to contribute to the health care reform debate. ...
... www.intelligenthospitals.com , , WINNIPEG, Sept. 16 ... pharmacy across North America, 77% of those looking to ... Intravenous Automation) - a self-contained unit for filling IV ... - as a vendor under consideration. The survey was ...
Cached Medicine News:Health News:Bitemark evidence and analysis should be approached with caution, according to UB study 2Health News:Bitemark evidence and analysis should be approached with caution, according to UB study 3Health News:MHA Announces Release of RxPertise(TM) 8.0 2Health News:Internet Can Help Curb Drinking Among College Students 2Health News:Pennsylvania Breast Cancer Coalition Hosts Annual Conference 2Health News:El Camino Hospital Provides Local Perspective on Health Care Reform and Innovation at Silicon Valley Healthcare CEO Summit 2Health News:IH Systems RIVA Top Pick for Directors of Pharmacy 2
... The ABI Prism 7000 Sequence ... PCR system that detects and quantitates ... cycle-by-cycle detection of accumulated PCR product ... cycling, fluorescence detection, and application-specific software ...
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
Medicine Products: